Ascend Laboratories, LLC recalls
14 recalls filed under Ascend Laboratories, LLC. The most recent was published August 5, 2026.
-
Class III · 3 months ago
Ascend Laboratories, LLC Dabigatran Etexilate Capsules, 150 mg recall: Failed impurity/degradation specification: an OOS result observed in Related
Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total…
-
Class III · 3 months ago
Ascend Laboratories, LLC Dabigatran Etexilate Capsules, 75 mg recall: Failed impurity/degradation specification: an OOS result observed in Related
Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total…
-
Class III · 3 months ago
Ascend Laboratories, LLC Dabigatran Etexilate Capsules, 75 mg recall: Failed impurity/degradation specification: an OOS result observed in Related
Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total…
-
Class III · 3 months ago
Ascend Laboratories, LLC Dabigatran etexilate Capsules, 110 mg, 60-count carton recall: Failed Impurities/Degradation Specifications: OOS result was observed during
Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II…
-
Class II · 3 months ago
Ascend Laboratories, LLC Amlodipine and Olmesartan Medoxomil Tablets, 10 mg/20 mg recall: Failed Dissolution Specifications; Olmesartan Medoxomil content below
Failed Dissolution Specifications; Olmesartan Medoxomil content below specifications
-
Class III · 3 months ago
Ascend Laboratories, LLC Dabigatran etexilate Capsules, 150 mg, 20-count carton recall: Failed Impurities/Degradation Specifications: OOS result was observed during
Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II…
-
Class II · 4 months ago
Ascend Laboratories, LLC Minocycline Hydrochloride Extended-Release Tablets, USP recall: Failed Dissolution Specifications: An out-of-specification (OOS) result
Failed Dissolution Specifications: An out-of-specification (OOS) result was observed during the 9th month of dissolution test analysis
-
Class II · 5 months ago
Ascend Laboratories, LLC Amlodipine and Olmesartan Medoxomil Tablets, 5mg/40mg recall: Failed Dissolution Specifications: Olmesartan Medoxomil content below
Failed Dissolution Specifications: Olmesartan Medoxomil content below specifications
-
Class II · 5 months ago
Ascend Laboratories, LLC, Metoprolol Succinate Extended-Release recall: Failed Dissolution Specifications
Failed Dissolution Specifications
-
Class II · 1+ years ago
Ascend Laboratories, LLC Atorvastatin Calcium Tablets USP, 40 mg recall: Failed Dissolution Specifications
Failed Dissolution Specifications
-
Class II · 1+ years ago
Ascend Laboratories, LLC Atorvastatin Calcium Tablets USP, 10 mg recall: Failed Dissolution Specifications
Failed Dissolution Specifications
-
Class II · 1+ years ago
Ascend Laboratories, LLC Atorvastatin Calcium Tablets USP, 20 mg recall: Failed Dissolution Specifications
Failed Dissolution Specifications
-
Class II · 1+ years ago
Ascend Laboratories, LLC Atorvastatin Calcium Tablets USP, 80 mg recall: Failed Dissolution Specifications
Failed Dissolution Specifications
-
Class II · 1+ years ago
Ascend Laboratories, LLC Aripiprazole Tablets, USP, 10 mg, 30-count bottles recall: Superpotent drug
Superpotent drug
About this page
Ascend Laboratories, LLC appears here because a federal agency named it as the recalling firm or the brand on the label. A recall is not a judgement about everything the company sells — it covers only the lot codes and models listed in each notice.